Research programme: LHRH peptidomimetic antagonists - AEterna Zentaris

Drug Profile

Research programme: LHRH peptidomimetic antagonists - AEterna Zentaris

Alternative Names: AEZS-115; LHRH peptidomimetics - AEterna Zentaris/Solvay; ZEN-019

Latest Information Update: 23 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AEterna Zentaris Inc; Solvay Pharmaceuticals
  • Developer AEterna Zentaris Inc
  • Class
  • Mechanism of Action Gonadotropin releasing hormone inhibitors; LHRH receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Benign prostatic hyperplasia; Cancer; Endometriosis
  • Discontinued Endocrine disorders; Genitourinary disorders; Pregnancy

Most Recent Events

  • 11 May 2012 Preclinical development is ongoing in Cancer, Endometriosis and Benign prostatic hyperplasia
  • 16 Feb 2010 Solvay Pharmaceuticals has been acquired and merged into Abbott Laboratories
  • 14 Dec 2008 Preclinical pharmacodynamics data presented at the 31st Annual San Antonio Breast Cancer Symposium (SABCS-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top